
28 Oct 2002
CAVAMAX® cyclodextrins provide innovative solutions for pharmaceutical formulators
International Specialty Products (ISP) and Wacker-Chemie GmbH have formed a strategic alliance for the promotion and sale of Wacker’s CAVAMAX® cyclodextrins throughout the world, with the exception of Japan. This alliance combines Wacker’s leadership in product technology and manufacturing with ISP’s global pharmaceutical technical and marketing expertise.
With their greatly enhanced manufacturing efficiency and growing regulatory recognition, cyclodextrin products present the pharmaceutical industry with a number of significant benefits, as shown below. These are based on their unique ability to form inclusion complexes with apolar molecules and functional groups.
Cyclodextrins are produced by the enzymatic digestion of starch by cyclodextrin glycosyltransferase (CGTase).Different enzymes specifically produce cyclodextrins comprised of 6, 7 and 8 glucose units, known respectively as α, β and γ cyclodextrin. ISP, through its alliance with Wacker, is the only company to commercially supply α, β and γ cyclodextrins to the pharmaceutical industry. These products are offered under the registered trademarks of CAVAMAX® W6 Pharma, CAVAMAX® W7 Pharma and CAVAMAX® W8 Pharma.
CAVAMAX® cyclodextrins sold to the pharmaceutical industry are manufactured in accordance with the applicable provisions of U.S. Current Good Manufacturing Practice in Manufacturing, Packing or Holding Human Food, 21 C.F.R. Part 110, and ISO 9000 procedures. Being starch derivatives, the cyclodextrins are generally regarded as essentially non-toxic materials and have excellent safety profiles. As a result, they are gaining acceptance by the various food and pharmaceutical regulatory bodies throughout the world.
Reader enquiries
International Specialty Products - ISP
Sean Appleton
Communications Manager - Europe
ISP Europe
Waterfield, Tadworth
Surrey, KT20 5HQ
United Kingdom
Notes for editors
Wacker is a globally active company with a well-balanced mix of chemical and semiconductor operations that hold technology leadership positions in many markets and provide tailored solutions that create added value for customers. Wacker has four specialized, independently operating business divisions: Wacker Siltronic, Wacker Silicones, Wacker Specialities and Wacker Ceramics. With over 17,000 employees at 26 production sites and more than 100 subsidiary companies, offices and technical service centres worldwide, Wacker generates annual sales of approximately 2.8 billion Euro.
International Specialty Products (ISP) is a leading global supplier of specialty chemicals and performance-enhancing products for a wide variety of personal care, pharmaceutical, industrial, food and beverage applications. ISP produces more than 400 specialty chemicals, which it markets and sells worldwide. The company’s headquarters is located in Wayne, New Jersey, U.S.A.
Related images

CAVAMAX® cyclodextrins provide innovative solutions for pharmaceutical formulators
Editorial enquiries
Sean Appleton
International Specialty Products - ISP
Peter Ibes
EMG